579 related articles for article (PubMed ID: 29682484)
1. Adaptive Immunity to
Roberts LM; Powell DA; Frelinger JA
Front Cell Infect Microbiol; 2018; 8():115. PubMed ID: 29682484
[No Abstract] [Full Text] [Related]
2. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S
Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073
[TBL] [Abstract][Full Text] [Related]
3. Identification of a live attenuated vaccine candidate for tularemia prophylaxis.
Mahawar M; Rabadi SM; Banik S; Catlett SV; Metzger DW; Malik M; Bakshi CS
PLoS One; 2013; 8(4):e61539. PubMed ID: 23613871
[TBL] [Abstract][Full Text] [Related]
4. Aim2 and Nlrp3 Are Dispensable for Vaccine-Induced Immunity against Francisella tularensis Live Vaccine Strain.
Alqahtani M; Ma Z; Fantone K; Malik M; Bakshi CS
Infect Immun; 2021 Jun; 89(7):e0013421. PubMed ID: 33875472
[TBL] [Abstract][Full Text] [Related]
5. Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain.
Elkins KL; Cowley SC; Bosio CM
Microbes Infect; 2003 Feb; 5(2):135-42. PubMed ID: 12650771
[TBL] [Abstract][Full Text] [Related]
6. Progress, challenges, and opportunities in Francisella vaccine development.
Elkins KL; Kurtz SL; De Pascalis R
Expert Rev Vaccines; 2016 Sep; 15(9):1183-96. PubMed ID: 27010448
[TBL] [Abstract][Full Text] [Related]
7. Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis.
Kirimanjeswara GS; Olmos S; Bakshi CS; Metzger DW
Immunol Rev; 2008 Oct; 225():244-55. PubMed ID: 18837786
[TBL] [Abstract][Full Text] [Related]
8. Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells.
Griffin AJ; Crane DD; Wehrly TD; Bosio CM
Clin Vaccine Immunol; 2015 Jan; 22(1):119-28. PubMed ID: 25410207
[TBL] [Abstract][Full Text] [Related]
9. Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.
Jia Q; Bowen R; Dillon BJ; Masleša-Galić S; Chang BT; Kaidi AC; Horwitz MA
Sci Rep; 2018 May; 8(1):7009. PubMed ID: 29725025
[TBL] [Abstract][Full Text] [Related]
10. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.
Wayne Conlan J; Shen H; Kuolee R; Zhao X; Chen W
Vaccine; 2005 Mar; 23(19):2477-85. PubMed ID: 15752834
[TBL] [Abstract][Full Text] [Related]
11. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.
Sebastian S; Pinkham JT; Lynch JG; Ross RA; Reinap B; Blalock LT; Conlan JW; Kasper DL
Vaccine; 2009 Jan; 27(4):597-605. PubMed ID: 19022323
[TBL] [Abstract][Full Text] [Related]
12. Vaccination strategies for Francisella tularensis.
Isherwood KE; Titball RW; Davies DH; Felgner PL; Morrow WJ
Adv Drug Deliv Rev; 2005 Jun; 57(9):1403-14. PubMed ID: 15919131
[TBL] [Abstract][Full Text] [Related]
13. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
KuoLee R; Harris G; Conlan JW; Chen W
Vaccine; 2007 May; 25(19):3781-91. PubMed ID: 17346863
[TBL] [Abstract][Full Text] [Related]
14. Deletion of IglH in virulent Francisella tularensis subsp. holarctica FSC200 strain results in attenuation and provides protection against the challenge with the parental strain.
Straskova A; Cerveny L; Spidlova P; Dankova V; Belcic D; Santic M; Stulik J
Microbes Infect; 2012 Feb; 14(2):177-87. PubMed ID: 21930232
[TBL] [Abstract][Full Text] [Related]
15. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity.
Sebastian S; Dillon ST; Lynch JG; Blalock LT; Balon E; Lee KT; Comstock LE; Conlan JW; Rubin EJ; Tzianabos AO; Kasper DL
Infect Immun; 2007 May; 75(5):2591-602. PubMed ID: 17296751
[TBL] [Abstract][Full Text] [Related]
16. A Francisella tularensis subspecies novicida purF mutant, but not a purA mutant, induces protective immunity to tularemia in mice.
Quarry JE; Isherwood KE; Michell SL; Diaper H; Titball RW; Oyston PC
Vaccine; 2007 Mar; 25(11):2011-8. PubMed ID: 17241711
[TBL] [Abstract][Full Text] [Related]
17. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A.
Wu TH; Hutt JA; Garrison KA; Berliba LS; Zhou Y; Lyons CR
Infect Immun; 2005 May; 73(5):2644-54. PubMed ID: 15845466
[TBL] [Abstract][Full Text] [Related]
18. Mice sublethally infected with Francisella novicida U112 develop only marginal protective immunity against systemic or aerosol challenge with virulent type A or B strains of F. tularensis.
Shen H; Chen W; Conlan JW
Microb Pathog; 2004 Aug; 37(2):107-10. PubMed ID: 15312850
[TBL] [Abstract][Full Text] [Related]
19. A panel of correlates predicts vaccine-induced protection of rats against respiratory challenge with virulent Francisella tularensis.
De Pascalis R; Hahn A; Brook HM; Ryden P; Donart N; Mittereder L; Frey B; Wu TH; Elkins KL
PLoS One; 2018; 13(5):e0198140. PubMed ID: 29799870
[TBL] [Abstract][Full Text] [Related]
20. Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain.
Pechous R; Celli J; Penoske R; Hayes SF; Frank DW; Zahrt TC
Infect Immun; 2006 Aug; 74(8):4452-61. PubMed ID: 16861631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
